Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
CMMo/RH/2009
Phase 2 other completed
Quick answer
Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments. for Liver Transplant Rejection is a Phase 2 program (other) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lxo Ireland Designated Activity Company
- Indication
- Liver Transplant Rejection
- Phase
- Phase 2
- Modality
- other
- Status
- completed